TG Therapeutics Stock Falls Despite Q2 Revenue Beat and Raised Guidance

Shares of TG Therapeutics (NASDAQ: TGTX) fell in pre-market trading on Monday, sliding after the company released strong second-quarter financial results that nonetheless failed to meet elevated investor expectations.

The decline appears to be a "sell the news" event, where a stock's price falls after a positive announcement because the good news was already priced in by the market. Before the opening bell, the stock was down 4.7% to $49.60 per share.

Strong Quarter Fails to Impress

TG Therapeutics reported financial results that beat Wall Street estimates and included an upward revision to its full-year guidance. The company's performance was driven by the commercial momentum of its multiple sclerosis drug, Briumvi.

Key figures from the second-quarter report include:

• Total global revenue: $240.3 million, ahead of the analyst consensus of approximately $228.85 million.
• Raised 2026 Briumvi U.S. revenue guidance: Now forecast in a range of $890 million to $905 million.
• Raised 2026 global revenue guidance: Lifted to approximately $950 million.

Ad

Despite the strong operational results, the market had already anticipated significant growth, with expectations for a 63.5% revenue increase heading into the report. The stock's valuation had seemingly absorbed much of this optimism in advance.

Market Context and Outlook

The drop in TGTX shares was company-specific and occurred against a backdrop of a positive broader market, with the S&P 500, Dow Jones, and NASDAQ all trading higher in the pre-market session. The move also reflects significant divergence among analysts regarding the stock's valuation.

While some firms like Jefferies and B. Riley hold price targets of $83 and $86, respectively, Bank of America has maintained an Underperform rating with a $20 price target, highlighting underlying uncertainty. With the stock still trading well above its 52-week low of $25.28, investors will now turn their attention to the company's earnings call for further details. Key topics will include management's commentary on the path to a $1 billion annualized revenue run rate and the timeline for Phase 3 data on a subcutaneous version of Briumvi, expected near the end of the year.